In section Market Quotes

Exagen Shares Fall 33% After Third-Quarter Loss Misses Forecast

Exagen shares dropped 33% to $4.75 by midday Tuesday after the precision medicine company reported a third-quarter loss wider than analysts had forecast. The stock is down 22% this year, despite revenue growth from a year earlier.

By Money Talk·November 10, 2026·2 min read·97 reads

Exagen reported a net loss of $6.3 million, or 25 cents a share, for the quarter, compared with a loss of $7.1 million, or 31 cents a share, a year earlier. Analysts polled by FactSet had expected a loss of 18 cents a share.

Revenue increased to $18.4 million from $17.2 million a year earlier, slightly above analysts’ estimate of $18.3 million.

The company reiterated its full-year revenue guidance of $72 million to $75 million. Analysts expect revenue of $73.9 million.

Exagen Shares Fall 33% After Third-Quarter Loss Misses Forecast

Comments (0)